Top

Published in:

01-05-2019 | Parkinson's Disease | Original Article

Dopamine Cytotoxicity on SH-SY5Y Cells: Involvement of α-Synuclein and Relevance in the Neurodegeneration of Sporadic Parkinson’s Disease

Authors: Upasana Ganguly, Anirban Ganguly, Oishimaya Sen, Gargi Ganguly, Roberto Cappai, Arghyadip Sahoo, Sasanka Chakrabarti

Published in: Neurotoxicity Research | Issue 4/2019

Abstract

The cytotoxicity of dopamine on cultured cells of neural origin has been used as a tool to explore the mechanisms of dopaminergic neurodegeneration in Parkinson’s disease. In the current study, we have shown that dopamine induces a dose-dependent (10–40 μM) and time-dependent (up to 96 h) loss of cell viability associated with mitochondrial dysfunction and increased intra-cellular accumulation of α-synuclein in cultured SH-SY5Y cells. Dopamine-induced mitochondrial dysfunction and the loss of cell viability under our experimental conditions could be prevented by cyclosporine, a blocker of mitochondrial permeability transition pore, as well as the antioxidant N-acetylcysteine. Interestingly, the dopamine effects on cell viability and mitochondrial functions were significantly prevented by knocking down α-synuclein expression by specific siRNA. Our results suggest that dopamine cytotoxicity is mediated by α-synuclein acting on the mitochondria and impairing its bioenergetic functions.

Available only for authorised users

Banerjee K, Munshi S, Sen O, Pramanik V, Mukherjee TR, Chakrabarti S (2014) Dopamine cytotoxicity involves both oxidative and non-oxidative pathways in SH-SY5Y cells: potential role of alpha-synuclein overexpression and proteasomal inhibition in the etiopathogenesis of Parkinson’s disease. Parkinson’s Dis 2014. https://doi.org/10.1155/2014/878935

Bir A, Sen O, Anand S, Khemka VK, Banerjee P, Cappai R, Sahoo A, Chakrabarti S (2014) α-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson’s disease. J Neurochem 131:868–877CrossRefPubMed

Bisaglia M, Mammi S, Bubacco L (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 282:15597–15605CrossRefPubMed

Breydo L, Wu JW, Uversky VN (2012) α-Synuclein misfolding and Parkinson's disease. Biochim Biophys Acta 1822:261–285CrossRefPubMed

Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franco MW, O’Dell M, Li SW, Pan Y, Chung HD, Galvin JE (2008) Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 115:193–203CrossRefPubMed

Cappai R, Leck SL, Tew DJ, Williamson NA, Smith DP, Galatis D, Sharples RA, Curtain CC, Curtain CC, Ali FE, Cherny RA, Culvenor JG, Bottomley SP, Masters CL, Barnham KJ, Hill AF (2005) Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J 19:1377–1379CrossRefPubMed

Chan T, Chow AM, Cheng XR, Tang DWF, Brown IR, Kerman K (2012) Oxidative stress effect of dopamine on α-synuclein: Electroanalysis of solvent interactions. ACS ChemNeurosci 3:569–574

Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destée A (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364:1167–1169CrossRefPubMed

Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, Hastings TG, Kang UJ, Zhuang X (2008) Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28:425–433CrossRefPubMedPubMedCentral

Cheung Y-T, Lau WKW, Yu M-S, Lai CS-W, Yeung SC, So KF, Chang RCC (2009) Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 30:127–135CrossRefPubMed

Cicchetti F, Drouin-Ouellet J, Gross RE (2009) Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci 30:475–483CrossRefPubMed

Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha synuclein adduct. Science 294:1346–1349CrossRefPubMed

Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG (2015) Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol 14:855–866CrossRefPubMedCentralPubMed

Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, Hu X, McCoy J, Chu CT, Burton EA, Hastings TG, Greenamyre JT (2016) α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. Sci Transl Med 8:342ra78CrossRefPubMedCentralPubMed

Ding YM, Jaumotte JD, Signore AP, Zigmond MJ (2004) Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. J Neurochem 89:776–787CrossRefPubMed

Follmer C, Coelho-Cerqueira E, Yatabe-Franco DY, Araujo GD, Pinheiro AS, Domont GB, Eliezer D (2015) Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of α-Synuclein with the toxic dopamine metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). J Biol Chem 290:27660–27679CrossRefPubMedCentralPubMed

Freire C, Koifman S (2012) Pesticide exposure and Parkinson's disease: epidemiological evidence of association. Neurotoxicology 33:947–971CrossRefPubMed

Ganguly U, Chakrabarti SS, Kaur U, Mukherjee A, Chakrabarti S (2018) Alpha-synuclein, proteotoxicity and Parkinson's disease: search for neuroprotective therapy. Curr Neuropharmacol 16:1086–1097CrossRefPubMedCentralPubMed

Hastings TG (2009) The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease. J Bioenerg Biomembr 41:469–472CrossRefPubMed

Hisahara S, Shimohama S (2011) Toxin-induced and genetic animal models of Parkinson’s disease. Parkinson’s Dis 2011. https://doi.org/10.4061/2011/951709

Huenchuguala S, Sjödin B, Mannervik B, Segura-Aguilar J (2018) Novel alpha-synuclein oligomers formed with the aminochrome-glutathione conjugate are not neurotoxic. Neurotox Res. https://doi.org/10.1007/s12640-018-9969-0 [Epub ahead of print]

Jana S, Sinha M, Chanda D, Roy T, Banerjee K, Munshi S, Patro BS, Chakrabarti S (2011) Mitochondrial dysfunction mediated by quinine oxidation products of dopamine : implications in dopamine cytotoxicity and pathogenesis of Parkinson’s disease. Biochim Biophys Acta 1812:663–673CrossRefPubMed

Keller JN, Huang FF, Dimayuga ER, Maragos WF (2000) Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radic Biol Med 29:1037–104242CrossRefPubMed

Khan FH, Sen T, Maiti AK, Jana S, Chatterjee U, Chakrabarti S (2005) Inhibition of rat brain mitochondrial transport chain activity by dopamine oxidation products during extended in vitro incubation: implication for Parkinson’s disease. Biochim BiophysActa 1741:65–74

Kovalevich J, Langford D (2013) Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol 1078:9–21CrossRefPubMedCentralPubMed

Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38–48CrossRefPubMedCentralPubMed

Leong SL, Cappai R, Barnham KJ, Pham CL (2009a) Modulation of alpha-synuclein aggregation by dopamine: a review. Neurochem Res 34:1838–1846CrossRefPubMed

Leong SL, Pham CL, Galatis D, Fodero-Tavoletti MT, Perez K, Hill AF, Masters CL, Ali FE, Barnham KJ, Cappai R (2009b) Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation. Free Radic Biol Med 46:1328–1337CrossRefPubMed

Leong SL, Hinds MG, Connor AR, Smith DP, Illes-Toth E, Pham CL, Barnham KJ, Cappai R (2015) The N-terminal residues 43 to 60 form the interface for dopamine mediated α-synuclein dimerisation. PLoS One 10:e0116497CrossRefPubMedCentralPubMed

Li J, Zhu M, Manning-Bog AB, Di Monte DA, Fink AL (2004) Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J 18:962–964CrossRefPubMed

Li HT, Lin DH, Luo XY, Zhang F, Ji LN, Du HN, Song GQ, Hu J, Zhou JW, Hu HY (2005) Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J 272:3661–3672CrossRefPubMed

Litteljohn D, Mangano E, Clarke M, Bobyn J, Kerry Moloney K, Hayley S (2011) Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson’s disease. Parkinson’s Dis 2011. https://doi.org/10.4061/2011/713517

Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee VM (2012) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in non-transgenic mice. Science 338:949–953CrossRefPubMedCentralPubMed

Maruyama W, Shamoto-Nagai M, Akao Y, Riederer P, Naoi M (2006) The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells. J Neural Transm Suppl 70:125–132CrossRef

Mazzulli JR, Mishizen AJ, Giasson BI, Lynch DR, Thomas SA, Nakashima A, Nagatsu T, Ota A, Ischiropoulos H (2006) Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci 26:10068–10078CrossRefPubMedPubMedCentral

Mazzulli JR, Armakola M, Dumoulin M, Parastatidis I, Ichiropoulos H (2007) Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J Biol Chem 282:31621–31630CrossRefPubMed

Michel PP, Hirsch EC, Hunot S (2016) Understanding dopaminergic cell death pathways in Parkinson disease. Neuron 90:675–691CrossRefPubMed

Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, SchmitzY KDE, Kobayashi K, Edwards RH, Sulzer D (2009) Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron 62:218–229CrossRefPubMedCentralPubMed

Moussa CE, Mahmoodian F, Tomita Y, Sidhu A (2008) Dopamine differentially induces aggregation of A53T mutant and wild type alpha-synuclein: insights into the protein chemistry of Parkinson's disease. Biochem Biophys Res Commun 365:833–839CrossRefPubMed

Muñoz P, Cardenas S, Huenchuguala S, Briceño A, Couve E, Paris I, Segura-Aguilar J (2015) DT-Diaphorase prevents aminochrome-induced alpha-synuclein oligomer formation and neurotoxicity. Toxicol Sci 145:37–47CrossRefPubMedCentralPubMed

Nicotra A, Parvez SH (2000) Cell death induced by MPTP, a substrate for monoamine oxidase B. Toxicology 153:157–166CrossRefPubMed

Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H, Lee VM (2005) Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem 280:21212–21219CrossRefPubMed

Pardo B, Mena MA, Casarejos MJ, Paíno CL, De Yѐbenes JG (1995) Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res 682:133–143CrossRefPubMed

Pham CL, Leong SL, Ali FE, Kenche VB, Hill AF, Gras SL, Barnham KJ, Cappai R (2009) Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. J Mol Bio 387:771–785CrossRef

Schober A (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318:215–224CrossRefPubMed

Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT (2002) An in vitro model of Parkinson’s disease: linking mitochondrial impairment to altered α-Synuclein metabolism and oxidative damage. J Neurosci 22:7006–7015CrossRefPubMedPubMedCentral

St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, BT MLPJ (2007) Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem 100:1449–1457PubMed

Terron A, Bal-Price A, Paini A, Monnet-Tschudi F, Bennekou SH, EFSA WG EPI1 Members, Leist M, Schildknecht S (2018) An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition. Arch Toxicol 92:41–82CrossRefPubMed

Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC (2003) Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278:25009–25013CrossRefPubMed

Zeng X-S, Geng WS, Jia JJ (2018) Neurotoxin-induced animal models of Parkinson disease: pathogenic mechanism and assessment. ASN Neuro 10:1–15CrossRef

Zhou ZD, Lim TM (2009) Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones. Free Radic Res 43:417–430CrossRefPubMed

Title: Dopamine Cytotoxicity on SH-SY5Y Cells: Involvement of α-Synuclein and Relevance in the Neurodegeneration of Sporadic Parkinson’s Disease
Authors: Upasana Ganguly
Anirban Ganguly
Oishimaya Sen
Gargi Ganguly
Roberto Cappai
Arghyadip Sahoo
Sasanka Chakrabarti
Publication date: 01-05-2019
Publisher: Springer US
Keyword: Parkinson's Disease
Published in: Neurotoxicity Research / Issue 4/2019
Print ISSN: 1029-8428
Electronic ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-019-0001-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dopamine Cytotoxicity on SH-SY5Y Cells: Involvement of α-Synuclein and Relevance in the Neurodegeneration of Sporadic Parkinson’s Disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Impaired Spatial Cognition in Adult Rats Treated with Multiple Intracerebroventricular (ICV) Infusions of the Enteric Bacterial Metabolite, Propionic Acid, and Return to Baseline After 1 Week of No Treatment: Contribution to a Rodent Model of ASD

25C-NBOMe, a Novel Designer Psychedelic, Induces Neurotoxicity 50 Times More Potent Than Methamphetamine In Vitro

Eugenol Attenuates Scopolamine-Induced Hippocampal Cholinergic, Glutamatergic, and Mitochondrial Toxicity in Experimental Rats

Salicylate-Induced Ototoxicity of Spiral Ganglion Neurons: Ca2+/CaMKII-Mediated Interaction Between NMDA Receptor and GABAA Receptor

Bezafibrate In Vivo Administration Prevents 3-Methylglutaric Acid-Induced Impairment of Redox Status, Mitochondrial Biogenesis, and Neural Injury in Brain of Developing Rats

Asiatic Acid Attenuated Aluminum Chloride-Induced Tau Pathology, Oxidative Stress and Apoptosis Via AKT/GSK-3β Signaling Pathway in Wistar Rats